247 related articles for article (PubMed ID: 29295653)
1. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Cramer P; Fraser G; Santucci-Silva R; Grosicki S; Dilhuydy MS; Janssens A; Loscertales J; Rule S; Goy A; Traina S; Chan EKH; Diels J; Sengupta N; Mahler M; Salman M; Howes A; Chanan-Khan A
Leuk Lymphoma; 2018 Sep; 59(9):2075-2084. PubMed ID: 29295653
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
3. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
[TBL] [Abstract][Full Text] [Related]
4. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD
Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982
[TBL] [Abstract][Full Text] [Related]
6. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
7. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
8. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser GAM; Chanan-Khan A; Demirkan F; Santucci Silva R; Grosicki S; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Pavlovsky MA; Goy A; Mato A; Hallek M; Salman M; Tamegnon M; Sun S; Connor A; Nottage K; Schuier N; Balasubramanian S; Howes A; Cramer P
Leuk Lymphoma; 2020 Dec; 61(13):3188-3197. PubMed ID: 32762271
[TBL] [Abstract][Full Text] [Related]
9. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM; de Jong J; Neyens M; Cramer P; Demirkan F; Fraser G; Bartlett N; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Goy A; Ganguly S; Salman M; Howes A; Mahler M; De Nicolao G; Poggesi I
Pharm Res; 2019 May; 36(7):93. PubMed ID: 31044267
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
[TBL] [Abstract][Full Text] [Related]
11. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
[TBL] [Abstract][Full Text] [Related]
15. Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Danilov AV; Yimer HA; Boxer MA; Burke JM; Babu S; Li J; Mun Y; Trask PC; Masaquel AS; Sharman JP
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):121-128. PubMed ID: 34674981
[TBL] [Abstract][Full Text] [Related]
16. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
19. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
